MaaT Pharma unveils its 2025 half-year results

MaaT Pharma announced strong results for the first half of 2025. The Phase 3 trial for MaaT013 in acute graft-versus-host disease revealed an overall response rate of 62% at Day 28, with an estimated survival of 54% at one year. The company has submitted a Marketing Authorization Application (MAA) for Xervyteg® to the European Medicines Agency (EMA).

A licensing agreement with Clinigen will enable the therapy to be distributed in Europe, generating an initial payment of €10.5 million. MaaT Pharma has also secured €37.5 million in financing from the European Investment Bank to support its hematology-oncology programs.

Revenue reached €2.4 million, up 41% year-on-year, driven by strong demand for Xervyteg®. Cash of €15 million as of June 30, 2025, is expected to be sufficient until the end of February 2026.